Just one clarification, sir. This quarter, margin has gone up. But at the same time, we can see the working capital parallelly has gone up for us. And given the nature of the business, should we see this going forward, if we try to push or optimize working capital, we have to compromise on the margin as well. So this is the clarification I just wanted?
Without compromising on margin?
Congrats on a good set of numbers in a challenging time. Within the existing basket of commercial molecule and the molecule which are at the advanced stage of pipeline, how many do you think can become Rs. 400 - Rs. 500 crore of revenue per molecule the next 3-4 years?
Within the existing basket of commercial molecules and the molecules which are at advanced stage of pipeline, how many do you think can become Rs. 400 -500 crore of revenue per molecule in the next 3-4 years?